סוראמוקס % 50 וטרינרי
isra - vet 2000 ltd - amoxicillin trihydrate 50 g / 100 g - powder - for the treatment of respiratory disease due to actinobacillus pleuropneumoniae susceptible to amoxicillin in swines and broilers.
נורוקלב 250 מג טבליות ללעיסה לחתולים וכלבים וטרינרי
comex ltd - amoxicillin as trihydrate; clavulanic acid as potassium - טבליות לעיסות - clavulanic acid as potassium 50 mg; amoxicillin as trihydrate 200 mg
נורוקלב 50 מג טבליות ללעיסה לחתולים וכלבים וטרינרי
comex ltd - amoxicillin as trihydrate; clavulanic acid as potassium - טבליות לעיסות - clavulanic acid as potassium 10 mg; amoxicillin as trihydrate 40 mg
ארומזין
pfizer pfe pharmaceuticals israel ltd - exemestane - טבליות מצופות - exemestane 25 mg - exemestane - exemestane - aromasin is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. aromasin is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies. aromasin is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breas cancer following 2-3 years of initial adjuvant tamoxifen therapy.
סינולוקס lc וטרינרי
pfizer pharmaceuticals israel ltd - amoxicillin as trihydrate 200 mg/dose; clavulanic acid as potassium 55 mg/dose - suspension for injection - combinations - for the treatment of bovine mastitis in lactating cows. it has a broad spectrum of bactericidal activity against bacteria which are sensitive to synulox isolated from the bovine udder.
אוגמנטין תרחיף 125 מ"ג/5 מ"ל
glaxo smith kline (israel) ltd - amoxicillin as trihydrate 125 mg / 5 ml; clavulanic acid as potassium 31.25 mg / 5 ml - suspension - ampicillin and enzyme inhibitor - fot the treatment of lower respiratory tract infections, otitis media infections, sinusitis infections, acute pharyngitis, skin and soft tissues infections and urinary tract infections caused also by beta-lactamase producing organisms which are susceptible to augmentin and are resistant to other beta-lactam antibiotics.
אקסמסטאן טבע 25 מג
abic marketing ltd, israel - exemestane - טבליות מצופות פילם - exemestane 25 mg - exemestane - exemestane - exemestane teva® is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. exemestane teva® is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies.exemestane teva® is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breast cancer following 2-3 years of initial adjuvant tamoxifen therapy
ארימידקס
taro international ltd, israel - anastrozole - טבליות מצופות פילם - anastrozole 1.0 mg - anastrozole - anastrozole - treatment of advanced breast cancer in post menopausal women. efficay has not been demonstrated in estrogen receptor negative patients unless they had a previous positive clinical response to tamoxifen. adjuvant treatment of postmenopausal women with hormone receptor positive early invasive breast cancer. adjuvant treatment of early breast cancer in hormone receptor positive postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.
אנסטרוזול טבע
teva israel ltd - anastrozole - טבליה - anastrozole 1 mg - anastrozole - anastrozole - treatment of advanced breast cancer in post menopausal women. efficay has not been demonstrated in estrogen receptor negative patients unless they had a previous positive clinical response to tamoxifen. adjuvant treatment of postmenopausal women with hormone receptor positive early invasive breast cancer. adjuvant treatment of early breast cancer in hormone receptor positive postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.
אנסטרוזול טבע
teva israel ltd - anastrozole - טבליה - anastrozole 1 mg - anastrozole - anastrozole - treatment of advanced breast cancer in post menopausal women. efficay has not been demonstrated in estrogen receptor negative patients unless they had a previous positive clinical response to tamoxifen. adjuvant treatment of postmenopausal women with hormone receptor positive early invasive breast cancer. adjuvant treatment of early breast cancer in hormone receptor positive postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.